@article{0218e1780c724975a54025e4a2a9fe7c,
title = "Nuclear Export Inhibition for Radiosensitization: A Proof-of-Concept Phase 1 Clinical Trial of Selinexor (KPT-330) Combined With Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer",
author = "Lawrence, {Yaacov R.} and Einat Shacham-Shmueli and Nirit Yarom and Marat Khaikin and Moris Venturero and Sara Apter and Yael Inbar and Zvi Symon and Dan Aderka and Naama Halpern and Raanan Berger and Ben Boursi and Galia Jacobson and Stephen Raskin and Aliza Ackerstein and Ofer Margalit and Sarit Appel and Michael Schvimer and Marsha Crochiere and Fan Yang and Yosef Landesman and Tami Rashal and Sharon Shacham and Talia Golan",
note = "Funding Information: This investigator-initiated trial was supported by Karyopharm Therapeutics, Inc (Newton, MA). Funding Information: Disclosures: Yo.L., T.R., and S.S. are full-time employees of Karyopharm Therapeutics, and M.C. is a former employee. Y.R.L. reports the following: research funding from Karyopharm Therapeutics, Checkmate Pharmaceuticals, and Bristol-Myers Squibb, and pending research funding from Merck Serono; honoraria/consultancy fees from Bristol-Myers Squibb, Clinigen Group, and Roche Genetech; and stock ownership in Protean Biodiagnostics, Inc. ",
year = "2022",
month = oct,
day = "1",
doi = "10.1016/j.ijrobp.2022.05.026",
language = "אנגלית",
volume = "114",
pages = "250--255",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",
}
